Display options
Cite
Klubo-Gwiezdzinska J, Costello J, Jensen K, et al. Amifostine does not protect thyroid cancer cells in DNA damaging . Endocr Connect. 2017;6(7):469-478doi: 10.1530/EC-17-0138.
Klubo-Gwiezdzinska, J., Costello, J., Jensen, K., Patel, A., Tkavc, R., Van Nostrand, D., Burman, K. D., Wartofsky, L., & Vasko, V. (2017). Amifostine does not protect thyroid cancer cells in DNA damaging . Endocrine connections, 6(7), 469-478. https://doi.org/10.1530/EC-17-0138
Klubo-Gwiezdzinska, Joanna, et al. "Amifostine does not protect thyroid cancer cells in DNA damaging ." Endocrine connections vol. 6,7 (2017): 469-478. doi: https://doi.org/10.1530/EC-17-0138
Klubo-Gwiezdzinska J, Costello J, Jensen K, Patel A, Tkavc R, Van Nostrand D, Burman KD, Wartofsky L, Vasko V. Amifostine does not protect thyroid cancer cells in DNA damaging . Endocr Connect. 2017 Oct;6(7):469-478. doi: 10.1530/EC-17-0138. Epub 2017 Aug 08. PMID: 28790138; PMCID: PMC5597971.
Copy Download .nbib Format: NLM
Share it on

Endocr Connect. 2017 Oct;6(7):469-478. doi: 10.1530/EC-17-0138. Epub 2017 Aug 08.

Amifostine does not protect thyroid cancer cells in DNA damaging .

Endocrine connections

Joanna Klubo-Gwiezdzinska, John Costello, Kirk Jensen, Aneeta Patel, Rok Tkavc, Douglas Van Nostrand, Kenneth D Burman, Leonard Wartofsky, Vasyl Vasko

Affiliations

  1. National Institute of HealthNIDDK, Office 10 Center Drive, Bethesda, Maryland, USA.
  2. Division of EndocrinologyDepartment of Medicine, Medstar Washington Hospital Center, Washington Hospital Center, Northwest, Washington, District of Columbia, USA.
  3. Department of PediatricsUniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  4. Department of PathologyUniformed Services University of the Health Sciences, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
  5. Department of PediatricsUniformed Services University of the Health Sciences, Bethesda, Maryland, USA [email protected].

PMID: 28790138 PMCID: PMC5597971 DOI: 10.1530/EC-17-0138

Abstract

BACKGROUND: Amifostine is a potent scavenger of reactive oxygen species that is used for the salivary gland protection during therapy with radioactive iodine for thyroid cancer. There are no data on the potential effect of amifostine on thyroid cancer cells.

METHODS: We investigated the effects of the active form of amifostine (WR-1065) on the response of thyroid cancer cells to treatment with DNA-damaging agents. WR-1065 was examined in human thyroid cancer cell lines (FTC133, TPC1, BCPAP and C643) and embryonic fibroblast cells NIH3T3. DNA damage was induced by exposure to H

RESULTS: We demonstrated the selective action of WR-1065 (0.1 mM), which prevented oxidative stress-induced DNA damage in fibroblasts, but did not protect thyroid cancer cells from DNA damage and apoptosis documented by caspase-3 and PARP cleavage after exposure to H

CONCLUSIONS: Our data show that amifostine has no protective effect on thyroid cancer cells against DNA-damaging agents

© 2017 The authors.

Keywords: DNA damage; amifostine; radiation; thyroid cancer

References

  1. Clin Exp Otorhinolaryngol. 2016 Sep;9(3):244-51 - PubMed
  2. Strahlenther Onkol. 1999 Nov;175 Suppl 4:6-12 - PubMed
  3. Endocr Relat Cancer. 2009 Jun;16(2):491-503 - PubMed
  4. Thyroid. 2003 Mar;13(3):265-71 - PubMed
  5. J Clin Oncol. 1996 Jul;14(7):2101-12 - PubMed
  6. Life Sci. 1999;64(17):1525-32 - PubMed
  7. Carcinogenesis. 1997 Dec;18(12):2457-9 - PubMed
  8. Int J Oncol. 2010 Nov;37(5):1187-94 - PubMed
  9. Strahlenther Onkol. 1999 Feb;175(2):57-61 - PubMed
  10. Mol Cancer Ther. 2007 Mar;6(3):789-801 - PubMed
  11. J Clin Oncol. 1987 Apr;5(4):574-8 - PubMed
  12. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):553-63 - PubMed
  13. Leuk Res. 2000 Jun;24(6):519-25 - PubMed
  14. Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1778-85 - PubMed
  15. J Clin Oncol. 2000 Oct 1;18(19):3339-45 - PubMed
  16. Thyroid. 2016 Jan;26(1):1-133 - PubMed
  17. Drug Metabol Drug Interact. 2000;16(4):237-79 - PubMed
  18. J Clin Oncol. 1997 Aug;15(8):2850-7 - PubMed
  19. Support Care Cancer. 1998 Mar;6(2):155-60 - PubMed
  20. Cancer Gene Ther. 2006 Aug;13(8):806-14 - PubMed
  21. Oncol Rep. 2003 Sep-Oct;10(5):1609-13 - PubMed
  22. Clin Cancer Res. 1998 Feb;4(2):331-6 - PubMed
  23. Cancer Res. 2005 Oct 15;65(20):9517-24 - PubMed
  24. Oncogene. 2000 Feb 24;19(9):1206-14 - PubMed
  25. Lancet Oncol. 2003 Jun;4(6):378-81 - PubMed
  26. Br J Cancer. 2003 Mar 10;88(5):754-9 - PubMed

Publication Types